Article citationsMore>>

T. Cufer, E. Vrdoljak, R. Gaafar, et al., “Phase II, Open-Label, Randomized Study (SIGN) of Single-Agent Gefitinib (IRESSA) or Docetaxel as Second-Line Therapy in Patients with Advanced (Stage IIIb or IV) Non-Small-Cell Lung Cancer,” Anticancer Drugs, Vol. 17, No. 4, 2006, pp. 401-409. doi:10.1097/01.cad.0000203381.99490.ab

has been cited by the following article: